A Closer Look At (NYSE American: VNRX) And The Science Reshaping Early Cancer Detection

The field of epigenetics is rapidly turning what once felt impossible

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored A Closer Look At (NYSE American: VNRX) And The Science Reshaping Early Cancer Detection *Get Our Updates Faster—Tap Here To Receive SMS Alerts* July 30th Greetings, Friend! Our latest profile came out hot on Wednesday morning. Following our Tuesday night report on that Nasdaq idea after it closed at $5.80, it rifled a $7.55 high the next day. The result? A short term blast of approx. 30%. Now, on to the next idea... In a crowded diagnostics landscape, one clinical-stage company is quietly building something that could reshape how cancer is detected: earlier, cheaper, and at scale. Armed with a proprietary epigenetics platform and a growing body of peer-reviewed clinical data, this firm is advancing a liquid biopsy approach that sidesteps the complexity and cost plaguing most competitors. Strategic partnerships, expanding international trials, and a pipeline touching multiple high-prevalence cancers signal a company with momentum, not just promise. And with a low float of fewer than 11Mn shares and a strong analyst target pointing to potential quadruple-digit upside, this NYSE American profile is topping our watchlist: VolitionRx Limited (NYSE American: VNRX) is currently at the center of this transformation, developing simple, easy-to-use blood tests that identify specific biomarkers associated with cancer and other diseases. As the medical community shifts toward non-invasive diagnostics, this company's proprietary technology is positioning it to address some of the most significant challenges in modern healthcare. VolitionRx Limited Company Overview VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of nucleosomics. The company specializes in identifying and measuring nucleosomes in the blood, which are structures consisting of DNA wrapped around histone proteins. When cells are damaged or diseased, these nucleosomes are released into the bloodstream with specific epigenetic modifications. By detecting these signatures, VNRX aims to provide clinicians with a "window" into the body’s health without the need for invasive tissue biopsies. Operating primarily through its Nu.Q® platform, the company has developed a suite of assays designed for both human and animal health. The technology is versatile, with applications ranging from cancer screening to the monitoring of acute conditions like sepsis. Nu.Q® Technology The Company's patented Nucleosomics™ technology isolates circulating nucleosomes from the blood for quantification and analysis, to enable earlier diagnosis and monitoring of life-altering diseases. Patented Nucleosomics™ Technology Their patented Nucleosomics™ technology isolates circulating nucleosomes from the blood for quantification and analysis. Based on this core, cutting-edge technology, VolitionRx has developed a portfolio of Nu.Q® assays which are simple, low-cost, accessible, routine blood tests. Their tests are platform agnostic so can be adapted to any workflow setting – manual, reference laboratory and point-of-care. VolitionRx's technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of disease enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment. Epigenetic changes can be detected before the diseased cells themselves become abnormal enough to show up in traditional biopsies, and oftentimes before the first symptoms are felt. VolitionRx aims to replace unpleasant, invasive, and often expensive screening and diagnostic tests with Nu.Q® blood tests, helping to save lives and to reduce overall health care costs. Robust Intellectual Property and Pipeline The company’s growth is underpinned by an extensive patent portfolio covering its nucleosome detection methods. Grab Sources And More Here: VNRX Website. VNRX Presentation. ----- 5 Potential Catalysts Put (NYSE American: VNRX) Atop Our Watchlist This Week #1. An Analyst $16.83 Target May Be Signaling Quadruple-Digit Potential Upside. Back in April, Zacks Small Cap Research analyst, Steven Ralston, updated coverage on (NYSE American: VNRX) with a price forecast of $16.83. From Wednesday's close, the target suggests a potential upside over 2,000%. Here's some highlights from the report: Valuation Utilizing a financial model based on DCF methodology, which forecasts out to 2033, and uses a 10% discount rate (based on CAPM), a 2% terminal growth rate and a terminal P/S multiple of 0.56, the indicated value of VNRX is $16.83 per share. ... #2. VNRX Has A Fairly Low Float (The Potential For Volatility Could Be Significant). With a float of roughly 10.26Mn shares, according to MarketBeat, the potential for volatility could be present daily. #3. A Potential Healthy Reversal Could Be Approaching For VNRX. Technical analysis reveals VNRX has several oversold indicators, suggesting a possible reversal setup may be developing. At 4:00PM EST on Wednesday, VNRX had a 9 and 14-Day Relative Strength Index both below 23% and a 9 and 14-Day Raw Stochastic below 9%. These technical levels suggest a profile that may be currently undervalued. #4. VolitionRx Announces Data Showing The Prognostic Value Of Its Nu.Q® Cancer Test. VolitionRx’s Nu.Q® Cancer test delivers breakthrough prognostic insights for newly diagnosed lung cancer patients, enabling clinicians to better predict survival and treatment response. Developed with France’s Hospices Civils de Lyon, the assay measures H3K27Me3-nucleosome levels to stratify patients into risk groups and guide curative care decisions.  Simple to implement, it empowers doctors and patients to co-create personalized treatment plans, enhancing outcomes especially for ctDNA-negative cases. This real-world evidence positions Nu.Q® as a routine, practice-changing tool poised for clinical adoption once approved. #5. Strategic Sysmex Synergy Scales Nu.Q® NETs Opp. VolitionRx has partnered with global diagnostics leader Sysmex to optimize its Nu.Q® NETs H3.1 assay on Sysmex’s widely installed analyzer platform. This collaboration accelerates Volition’s out-licensing strategy, leveraging Sysmex’s regulatory expertise and disease-state knowledge to bring the test to market faster.  Focused on NETosis-linked conditions like sepsis, the assay promises low-cost, high-value monitoring and decision support for clinicians. With a $3.8Bn addressable market, the alliance marks a potential commercial milestone for Volition’s epigenetic portfolio. ----- We're initiating coverage on VolitionRx Limited (NYSE American: VNRX). Keep your eyes peeled for updates heading out soon.  All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice